The efficacy of PSA screening: impact of key components in the ERSPC and PLCO trial

BACKGROUND: The European Randomized Study of Screening for Prostate Cancer (ERSPC) showed that prostate-specific antigen (PSA) screening significantly reduced prostate cancer mortality (rate ratio (RR)=0.79, 95%CI 0.69–0.91). The U.S. Prostate, Lung, Colorectal, and Ovarian (PLCO) trial showed no su...

Full description

Saved in:
Bibliographic Details
Published in:Cancer
Main Authors: de Koning, Harry J, Gulati, Roman, Moss, Sue M, Hugosson, Jonas, Pinsky, Paul F, Berg, Christine D, Auvinen, Anssi, Andriole, Gerald L, Roobol, Monique J, Crawford, E. David, Nelen, Vera, Kwiatkowski, Maciej, Zappa, Marco, Luján, Marcos, Villers, Arnauld, de Carvalho, Tiago M, Feuer, Eric J, Tsodikov, Alex, Mariotto, Angela B, Heijnsdijk, Eveline AM, Etzioni, R
Format: Artigo
Language:Inglês
Published: 2017
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5839977/
https://ncbi.nlm.nih.gov/pubmed/29211316
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.31178
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items